Drug
Enlonstobart clinical trials
Also written SG001.
- studies test it
- 17
- open now
- 13
- in phase 3
- 5
- first study started
- 2019
Keep track of what changes. Save the enlonstobart studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
17 studies that test it; most in 2025 (6)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 14
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 4
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (7) · CSPC Megalith Biopharmaceutical Co.,Ltd. (3) · Shanghai JMT-Bio Inc. (2) · Fudan University (1) · Shanghai Chest Hospital (1) · Sun Yat-Sen University Cancer Center (1) · Chongqing University Cancer Hospital (1) · Shanghai Runshi Pharmaceutical Technology Co., Ltd (1)
Often tested with
Tested in the same studies.
Anti-EGFR Antibody-drug Conjugate CPO301 (3) · Pembrolizumab (2) · Modified FOLFOX6 Regimen (1) · Suvemcitug (1) · SYHX2011 (1) · Anbenitamab (1) · Trastuzumab (1) · Liposomal Mitoxantrone Hydrochloride (1)
Studies
Open first, then newest update. How each study uses enlonstobart is read from its arms, and is right about nine times in ten.
Testing it · 17
- SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell CarcinomaRecruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07254585Written as Enlonstobart injection
- Total Neoadjuvant mFOLFOX6 Plus Suvemcitug and Enlonstobart With Selective Omission of Pelvic Radiotherapy for High-Risk Mid-Rectal Locally Advanced Rectal CancerNot yet recruitingPhase 2Fudan UniversityNCT07810114Written as Enlonstobart
- SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung CancerNot yet recruitingPhase 2/3Shanghai Chest HospitalNCT07662811Written as Enlonstobart
- SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07633873Written as Enlonstobart injection
- A Study of KN026-based Combination Therapy in HER2-positive Gastric CancerNot yet recruitingPhase 2/3Shanghai JMT-Bio Inc.NCT07332533Written as Enlonstobart
- Mitoxantrone Hydrochloride Liposome and Enlonstobart Combination Treatment in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)Not yet recruitingPhase 1/2Sun Yat-Sen University Cancer CenterNCT07288814Written as Mitoxantrone Hydrochloride Liposome & Enlonstobart
- Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07282509Written as Enlonstobart Injection
- A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.Not yet recruitingPhase 2/3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07251062Written as SYS6010+SG001
- A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerNot yet recruitingPhase 2Chongqing University Cancer HospitalNCT06981858Written as Enlonstobart Injection
- A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.Not yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT06136988Written as SG001
- A Study of Simmitinib Plus SG001 in Advanced Solid TumorsNot yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06132217Written as SG001
- A Study of JMT101 in Patients With Metastatic Colorectal CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06089330Written as SG001
- Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)Not yet recruitingPhase 3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05715840Written as SG001 injection
- Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical CancerStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04886700Written as SG001
- A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)Status unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05068141Written as SG001
- Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCStatus unknownPhase 2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT04983550Written as SG001
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursStatus unknownPhase 1CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT03852823Written as SG001
Given in every arm · 7 — enlonstobart is usual care beside what is tested
- A Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)Not yet recruitingPhase 3CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07672223Written as Enlonstobart
- SYS6006 in Combination With Enlonstobart Injection Versus Enlonstobart Injection in Participants With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT07622225Written as Enlonstobart
- Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R)RecruitingPhase 2Fudan UniversityNCT07183865Written as SG001
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCNot yet recruitingPhase 2CSPC Megalith Biopharmaceutical Co.,Ltd.NCT06989671Written as SG001
- JSKN003 Combined Treatment of HER2-positive Gastric CancerNot yet recruitingPhase 2Shanghai JMT-Bio Inc.NCT06998771Written as Enlonstobart
- A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingPhase 1/2CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT05508659Written as SG001
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract CancerTerminatedPhase 2CSPC Ouyi Pharmaceutical Co., Ltd.NCT05009953Written as SG001
As the comparator · 1 — what is tested is compared with enlonstobart
Codes
What other systems call enlonstobart · ClinicalTrials.gg INT016745
- UNII (FDA) H533QU433MENLONSTOBARTOne source FDA
- NCI Thesaurus C182009EnlonstobartOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H533QU433M | ENLONSTOBART | One source FDA |
| NCI Thesaurus | C182009 | Enlonstobart | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.